Lee Sung 4
4 · CYTOKINETICS INC · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
Cytokinetics (CYTK) CFO Lee Sung Receives Equity Awards
What Happened
Lee Sung, Chief Financial Officer of Cytokinetics (CYTK), received annual equity awards on March 15, 2026: 20,646 restricted stock units (RSUs) and two stock-option grants totaling 31,145 options (1,665 and 29,480). The transactions are recorded as awards/grants (code A) at an acquisition price of $0.00 (i.e., compensation grants), so the Form 4 shows $0 cash change on acquisition. If all RSUs convert and options are exercised, the awards would represent up to 51,791 underlying shares.
Key Details
- Transaction date: 2026-03-15; Form 4 filed 2026-03-17 (no late filing indicated in the filing excerpt).
- Awards: 20,646 RSUs (F1); 1,665 options (F2); 29,480 options (F3). Reported acquisition price: $0.00 for each grant.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnotes/vesting:
- F1 (RSUs): convert 1:1 to common shares; vest 40% at 1 year, additional 40% at 2 years, final 20% at 3 years, subject to continued employment and the 2004 Equity Incentive Plan.
- F2/F3 (options): vest in 48 equal monthly installments, subject to continued employment and the 2004 Equity Incentive Plan.
- Transaction code: A = Award/Grant (not an open-market buy or sale).
Context
RSUs convert directly to shares when they vest; stock options are derivative securities that must be exercised (and may require payment of an exercise price) to become shares. Grants recorded at $0.00 are standard for equity compensation filings and reflect the grant event, not the market value realized. Such awards are part of routine executive compensation and do not by themselves indicate an immediate buy/sell signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-15+20,646→ 92,062 total - Award
Incentive Stock Option (Right to Buy)
[F2]2026-03-15+1,665→ 1,665 totalExercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (1,665 underlying) - Award
Non-Qualified Stock Option (Right to Buy)
[F3]2026-03-15+29,480→ 29,480 totalExercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (29,480 underlying)
Footnotes (3)
- [F1]Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
- [F2]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
- [F3]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.